Browse the evidence

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) significantly improve pain and function in patients with obesity and moderate-to-severe knee osteoarthritis, achieving clinical benefits comparable to or exceeding standard therapies like NSAIDs and physical therapy.

If you have knee osteoarthritis and a BMI over 30, GLP-1 medications like semaglutide (2.4 mg weekly) can significantly reduce pain and improve function, potentially delaying or avoiding surgery. This works not just by helping you lose weight, but by directly reducing inflammation in the joint. Current guidelines suggest aiming for more than 7-10% weight loss for maximum benefit, which these drugs help achieve more effectively than lifestyle changes alone for many people.

Once-weekly subcutaneous semaglutide 2.4 mg combined with diet and exercise reverses prediabetes in approximately 80% of patients with obesity, significantly outperforming diet and exercise alone (12% reversal rate).

If you have obesity and prediabetes, adding once-weekly semaglutide 2.4 mg to your diet and exercise plan significantly increases your chances of reversing prediabetes (from 12% to 80%). This treatment also lowers BMI by ~14% and reduces cardiovascular risks. It requires weekly injections and ongoing lifestyle efforts, as stopping the drug may lead to weight regain and return of prediabetes.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce significant weight loss (14.9%–20.9%) and improve fertility in obese individuals, particularly those with PCOS, by acting on hypothalamic and brainstem regions to suppress appetite and stimulate GnRH/LH release.

GLP-1 agonists like semaglutide and tirzepatide are highly effective for significant weight loss and can improve fertility in obese individuals, especially those with PCOS. However, they come with high rates of gastrointestinal side effects and weight regain upon discontinuation. They should be used under medical supervision, with careful attention to dosing and long-term management strategies.

Weekly tirzepatide injections combined with dietician support reduce OSA severity by approximately 50% in obese patients with moderate to severe OSA.

If you are obese and have moderate to severe sleep apnea, ask your doctor about tirzepatide. This weekly injection, combined with dietary support, has been shown to cut your apnea severity in half. It is FDA-cleared for this use and may improve your blood pressure and sleep quality, though you should expect some mild stomach issues initially.

Melanocortin-4 receptor (MC4R) agonists significantly reduce body weight, BMI, and hunger scores in patients with obesity, including those with rare genetic syndromes.

If you have obesity, particularly if it is linked to a rare genetic condition, MC4R agonist drugs like setmelanotide can significantly reduce your body weight, BMI, and hunger. These drugs work by activating receptors in your brain that control satiety and energy expenditure. Treatment involves daily subcutaneous injections, with doses adjusted based on your age and how well you tolerate the medication. While lifestyle changes are important, they often lead to modest and unsustainable weight loss, making these drugs a valuable option for those who struggle with conventional methods.

GLP-1 receptor agonists reduce food intake, increase satiety, delay gastric emptying, and improve glucose tolerance, leading to weight loss in humans.

GLP-1 receptor agonists are a proven, FDA-approved treatment for obesity and type 2 diabetes. They work by reducing appetite and improving metabolic function. Consult a healthcare provider to see if this treatment is appropriate for you.

Orforglipron 45 mg significantly reduces BMI, body weight, waist circumference, and HbA1c in patients with T2DM or obesity, with efficacy increasing at higher doses.

If you have T2DM or obesity, the 45 mg dose of oral orforglipron is highly effective for reducing weight and blood sugar. It works by mimicking a gut hormone to control appetite and insulin. Expect significant results, but be aware of potential side effects like nausea.

Next-generation GLP-1 based therapies (oral formulations, small-molecule agonists, multi-receptor agonists) aim to achieve greater efficacy (>25% weight loss), improved tolerability, and novel delivery platforms.

Next-generation GLP-1 based therapies aim to achieve greater weight loss (>25%), improved tolerability, and novel delivery platforms, including oral formulations and small-molecule agonists. These therapies are currently in clinical trials and represent the future direction of obesity treatment.

GLP-1 receptor agonists (liraglutide 3 mg, semaglutide 2.4 mg) and tirzepatide are effective first-line pharmacological treatments for obesity in psoriasis patients, providing significant weight loss and independent improvements in psoriasis severity (PASI scores) through anti-inflammatory mechanisms.

If you have psoriasis and obesity, GLP-1 drugs like semaglutide or tirzepatide are highly effective first-line treatments. They help you lose significant weight and can directly reduce your psoriasis severity, not just through weight loss but by lowering inflammation. Start with lifestyle changes, but if you need medication, these drugs are safe and effective. Work with your doctor to find the right dose and manage any initial stomach side effects by starting low and going slow.

GLP-1 agonist semaglutide produces significant weight loss (12.7%) and improves cardiometabolic risk in adults with obesity, with transient mild-to-moderate nausea and diarrhea as primary side effects.

If you have obesity and meet the criteria (BMI ≥30 or ≥27 with complications), discuss GLP-1 agonists like semaglutide with your doctor. This medication can lead to substantial weight loss (around 12.7% in studies) and improves blood sugar and heart disease risk. Common side effects like nausea or diarrhea are usually temporary and manageable.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) produce significant weight loss (6.2–15.8 kg) in adults with obesity, with efficacy increasing with higher doses.

GLP-1 agonists like semaglutide and liraglutide are effective for significant weight loss in adults with obesity, often outperforming lifestyle changes alone. Expect weight loss between 6-16 kg over several months. Be aware of gastrointestinal side effects, which are common but often manageable. These are prescription medications requiring medical supervision to manage dosing and side effects.

Semaglutide (2.4 mg weekly) produces significant weight loss (10-15%) in adults with obesity by slowing gastric emptying and reducing appetite, but discontinuation leads to substantial weight regain, necessitating continuous treatment.

Semaglutide 2.4mg weekly is a highly effective tool for significant weight loss (10-15%) in obesity, working by reducing appetite and slowing digestion. However, it is not a cure; stopping the medication typically leads to regaining most of the lost weight. It works best when combined with lifestyle changes and requires ongoing medical supervision to manage side effects like nausea and to ensure long-term success.

Semaglutide 2.4 mg administered once weekly produces significant weight loss (mean 14.9%) in adults with obesity or overweight, superior to placebo, when combined with lifestyle interventions.

Semaglutide 2.4mg weekly, combined with diet and exercise, leads to substantial weight loss (approx 15%) in obese adults without diabetes. Expect potential nausea, which often subsides. It is more effective than older drugs like orlistat and requires weekly injection rather than daily.

GLP-1 receptor agonists (GLP1RAs) such as semaglutide and liraglutide induce significant weight loss (5-15%) and improve metabolic markers by delaying gastric emptying, suppressing appetite via central nervous system signaling, and enhancing glucose-dependent insulin secretion.

GLP-1 medications like semaglutide and liraglutide are highly effective for weight loss (5-22%) and metabolic health. They work by slowing digestion and signaling fullness to the brain. Start with the lowest dose to minimize nausea, which usually improves over time. Combine with a calorie-controlled diet and exercise for best results. Oral versions exist but may have different absorption requirements.

GLP-1 analogues (liraglutide, semaglutide, tirzepatide, efpeglenatide) combined with lifestyle interventions produce significant weight loss (5-15%) and reduce cardiometabolic risk in adults with obesity.

GLP-1 medications like semaglutide and liraglutide are effective tools for weight loss when combined with diet and exercise. They work by slowing digestion and reducing appetite. While gastrointestinal side effects like nausea are common, they often subside. These drugs are approved for adults with high BMI or obesity-related comorbidities.

Administration of GLP-1 receptor agonists (semaglutide 2.4 mg weekly or liraglutide 3.0 mg daily) combined with lifestyle interventions significantly reduces body weight and modulates gut microbiota composition in adults with obesity.

If you have obesity, GLP-1 medications like semaglutide (2.4 mg weekly) or liraglutide (3.0 mg daily) are highly effective for weight loss when combined with lifestyle changes. They work by mimicking hormones that regulate blood sugar and gut health, leading to significant weight reduction and improved metabolic markers.

Tirzepatide (5, 10, and 15 mg) is a cost-effective treatment for weight management compared to liraglutide in the UK, demonstrating dominance (cost savings and QALY gains) in the general obesity trial population and favorable ICERs in the specific NICE-reimbursed population.

For patients in the UK with obesity or overweight plus complications, tirzepatide (5, 10, or 15 mg weekly) combined with diet and exercise is a cost-effective treatment option compared to liraglutide. It offers potential cost savings and quality-of-life gains, and unlike liraglutide which is restricted to specialist services, tirzepatide can be prescribed in primary care.

Tirzepatide reduces the incidence of obesity-related complications, specifically knee replacements (29-46% reduction) and type 2 diabetes (25-48% reduction), compared to liraglutide.

Tirzepatide treatment is associated with significantly lower rates of knee replacements and type 2 diabetes compared to liraglutide, likely due to greater weight loss and prediabetes reversal.

Dual incretin agonists (e.g., tirzepatide) and newer GLP-1 receptor agonists (e.g., semaglutide) provide superior glycaemic control and greater weight reduction compared to earlier GLP-1 agents.

If you have Type 2 Diabetes, newer injectable medications like tirzepatide or semaglutide are significantly more effective at lowering blood sugar and reducing weight than older GLP-1 drugs. Discuss these options with your doctor, especially if you are struggling with weight or glucose control despite previous treatments.

Long-acting GLP-1 receptor agonists (semaglutide and dulaglutide) provide superior efficacy, particularly in cardio-renal protection, and overall value compared to other long-acting GLP-1RAs in China, earning strong clinical recommendations.

For patients with Type 2 Diabetes in China, Semaglutide and Dulaglutide are the preferred long-acting GLP-1 receptor agonists. They offer strong recommendations due to superior efficacy, particularly in protecting the heart and kidneys, and better overall value. While newer drugs like Tirzepatide show great potential for weight loss and glucose control, their high cost and lack of insurance coverage make them less accessible. Patients should discuss these options with their doctors, prioritizing agents with established cardiovascular benefits and insurance coverage.

Treatment with tirzepatide (10-15 mg weekly) causes significant shifts to lower BMI categories in adults with obesity, which is associated with substantial improvements in cardiometabolic risk factors including blood pressure, fasting insulin, and lipid profiles.

If you have obesity or overweight with related health issues like high blood pressure or high cholesterol, talk to your doctor about tirzepatide. It is a once-weekly injection that helps many people move to a lower BMI category, which is linked to better heart health and metabolic markers. It works best when combined with a reduced-calorie diet and increased physical activity.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces significant weight loss (exceeding 20% body weight in some cases) and improves glycemic control in patients with type 2 diabetes and obesity.

Tirzepatide is a weekly injection that mimics gut hormones to significantly reduce weight (often >20%) and improve blood sugar. It works best when paired with diet and exercise. Start with lower doses to minimize stomach issues like nausea, which usually improve over time.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces significant weight loss (8.6% to 20.9%) and metabolic improvements in obese patients, outperforming placebo and demonstrating superior efficacy compared to semaglutide in head-to-head comparisons.

Tirzepatide is a once-weekly injection that helps obese patients lose significant weight (up to 20%) and improves blood sugar and heart risk factors. It works by mimicking hormones that regulate appetite and digestion. While it can cause temporary stomach issues like nausea, it is generally well-tolerated and more effective than some other existing weight-loss drugs. Medical supervision is required to manage dosing and side effects.

GLP-1 agonists (semaglutide 2.4 mg SC weekly and tirzepatide 5-15 mg SC weekly) produce profound weight loss (15-21% body weight reduction) in overweight/obese adults, significantly outperforming placebo and existing pharmacologic strategies like metformin.

If you are struggling with significant weight gain, particularly from psychiatric medications, GLP-1 agonists like semaglutide or tirzepatide offer the most effective pharmacological solution currently available, capable of producing 15-20% body weight loss. These require weekly injections and lifestyle changes, and while they cause transient gastrointestinal side effects, their efficacy far exceeds older options like metformin. Consult your provider to see if you qualify based on BMI and medical history.